Q1 2027 Financial Results for the Fiscal Year Ending March 2027 (Japan GAAP) (Consolidated)

Business Performance Overview

For the first quarter cumulative period, revenue grew 5.4% year over year to 16,865 million yen as a result of expanding digital and AI-enabled services and steady progress in DX and GX-related initiatives. Operating income rose 67.4% to 344 million yen, ordinary income increased 80.3% to 444 million yen, and net income attributable to owners of the parent grew 79.3% to 115 million yen, marking significant improvement. By segment, Corporate Doctor Group revenue was 8,659 million yen with segment profit of 187 million yen, and Business Solution Group revenue was 8,205 million yen with segment profit of 154 million yen. Although costs associated with new investments increased, overall efficiency and growth strategy were balanced.

Financial Position and Dividend Outlook

Total assets at quarter-end stood at 38,159 million yen, net assets 20,796 million yen, and equity ratio 48.2%. The full-year dividend is expected to be 32 yen. There are no changes to the full-year earnings guidance, and the policy remains to continue growth investments while sustaining shareholder returns.